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were used as denominators in the calculation of incremental CE ratios (ICER) are 
decreased frequencies of mild hypoxia, severe hypoxia and pneumonia. RESULTS: 
Frequencies of residual NMB were estimated as 51.2% 44.6% and 0.4% in SR, 
neostigmine and Bridion groups, respectively. Hypoxia rate was calculated as 27.4% 
and 11.4% in patients with and without residual NMB. Frequencies of pneumonia 
were 17.2% and 5.9% in patients with and without residual NMB. Percentage of 
patients without any complication was found to be 88.0% in Bridion group, while it 
was 73.8% and 75.7% in SR and neostigmine groups. The costs of complications 
were 126.45c and 114.56c in SR and neostigmine groups, while it was only 34.93c in 
Bridion® group. When medication cost was added, the total cost rose to 114.62c in 
Bridion® group, which was still lower than the total costs of SR and neostigmine 
groups. The rate of severe hypoxia was estimated as 7.9% in Bridion® group, while 
it was 13.5% and 12.7% in SR and neostigmine groups, respectively. Pneumonia was 
seen in 1.2% of the patients in Bridion® group, while the frequencies of pneumonia 
were 9.4% and 8.3% in SR and neostigmine groups. CONCLUSIONS: Bridion® was 
found to be dominant to both SR and neostigmine groups, in terms of decrease in 
frequencies of hypoxia and pulmonary complications.
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COST-EFFECTIVENESS EVALUATION OF LEVODOPA/CARBIDOPA/
ENTACAPONE IN TREATMENT OF PARKINSON DISEASE
Yagudina R, Kulikov AU, Serpik VG
Moscow Medical Academy, Moscow, Russia
OBJECTIVES: To conduct pharmacoeconomic evaluation of Levodopa/Carbidopa/
Entacapone (LCE) compared to standard therapy in Parkinson disease treatment. 
Standard therapy was presented by Levodopa and Carbidopa. METHODS: The cost-
effectiveness study was carried conducted. Effectiveness was measured in DALYs. 
Time horizont for cost-effectiveness analysis was 2 years. a 3% discount rate was 
used. 1 EUR = 40 RUB. RESULTS: LCE provided beneﬁ ts in effectiveness compared 
to standard therapy. LCE reduced days incapacity index twice from 44 to 21 days. 
Two year pilot study showed that LCE provided 0,83 DALY, than standard therapy 
presented 0,5 DALY. Also administration of LCE reduced daily Levodopa dose on 
68 mg. Total annual costs for LCE therapy were 158 938 (3 974 EUR) RUB. Standard 
therapy total costs varied from 129 113 RUB (3 228 EUR) to 145 422 RUB (3 636 
EUR) yearly according to disease progression grade. Indirect costs, including GDP 
losses due to temporary disability and payments for temporary disability, were 14 372 
RUB (359 EUR) for LCE and 30 113 RUB (753 EUR) for standard therapy. The cost-
effectiveness ratio for LCE was 191 492 RUB (4 787 EUR) per DALY, than for 
standard therapy it was 258 326 RUB (6 458 EUR) per DALY. CONCLUSIONS: LCE 
demonstrates lower cost-effectiveness ratio (191 492 RUB) compared to standard 
Parkinson disease therapy (258 326 RUB), therefore LCE has an advantage over 
standard therapy in terms of pharmacoeconomic evaluation.
PND24
THE IMPACT OF COHORT SELECTION ON COST-EFFECTIVENESS 
RESULTS IN MULTIPLE SCLEROSIS
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OBJECTIVES: Adherence to cost-effectiveness analytic guidelines requires careful 
assessment of clinical trial results to ensure the most appropriate cohort data selection. 
This study examines the impact of cohort selection on the results of the Goldberg, et 
al. 2009 cost-effectiveness study of disease-modifying therapies (DMTs) in multiple 
sclerosis (MS). METHODS: Using intent–to-treat (ITT) two-year data from pivotal 
trials, Goldberg compared cost per relapse avoided of ﬁ rst-line DMTs. However, there 
are important differences in the ITT cohorts among the trials. Due to lower than 
expected subject drop-out rates, the interferon beta-1a IM (INF-b-1a-IM) trial was 
able to meet its primary endpoint with a reduced sample size and a decision was made 
to terminate the trial early. This resulted in almost half of the 301 ITT (or “all-
patient”) cohort being on study drug for less than two years. a second, “two-year” 
172 patient cohort consisted of patients who had completed two years on drug 
therapy. Goldberg used the INF-b-1a-IM “all-patient” cohort in his cost study. To 
test the impact of this cohort selection, we recreated Goldberg’s model using the “all-
patient” relapse rate (0.67 for INF-b-1a-IM vs. 0.82 for placebo) and then substituted 
the “two-year” cohort data (relapse rate of 0.61 for INF-b-1a-IM vs. 0.90 for placebo) 
and compared results. RESULTS: This study’s cost per relapse avoided was 45% lower 
for INF-b-1a-IM while the results for the other DMTs were comparable to those 
reported by Goldberg. Ranked from most to least cost-effective, the model results were 
$77,980 for INF-b-1a-IM, $80,121 for interferon beta-1a SC, $86,572 for interferon 
beta-1b, and $87,767 for glatiramer. CONCLUSIONS: Our analysis demonstrates the 
importance of cohort selection in cost-effectiveness analyses in MS. By selecting 
comparable cohort data from patients who had completed at least two years on study 
drug, we found that INF-b-1a-IM had the lowest cost per relapse avoided of all ﬁ rst-
line DMTs.
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RELAPSING REMITTING MULTIPLE SCLEROSIS IN 4 EUROPEAN 
COUNTRIES
Brennig C, Walter E, Schöllbauer V
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OBJECTIVES: Multiple sclerosis (MS) is an inﬂ ammatory, neurodegenerative condi-
tion of central nervous system with prevalence of 1 Million worldwide (age at ﬁ rst 
manifestation 20–40 years). MS may lead to permanent disability and early retirement 
even in young adults. The purpose of this analysis was to provide an economic assess-
ment of relapsing-remitting MS-treatment with Natalizumab versus Interferons and 
Copolymer in 4 European countries (Austria, Czech Republic, Slovakia, Slovenia). 
METHODS: The analysis was performed using a Markov model. The model allows 
a treatment switch due to relapse. Efﬁ cacy assessment was based on the outcome 
measure “relapse-free patients”. Costs were captured for the year 2010. Resource use 
was determined from results of a survey conducted by the Austrian MS Society and 
accurately reﬂ ects the therapeutic approach. Resource use of Czech Republic, Slovakia 
and Slovenia was determined via country-speciﬁ c research. Where country speciﬁ c 
data could not be captured, Austrian data was adjusted via Purchasing Power Parities 
(PPP). The study time horizon was 2 years. The analysis was performed from the 
perspective of the health care system of the 4 European countries. RESULTS: In Czech 
Republic the average cost of the therapy algorithm Natalizumab amount to c33,835 
per patient within the time horizon of 2 years versus c22,896 (Interferon) and c21,256 
(Copolymer). a patient successfully treated with Natalizumab accounts for c56,525 
compared to c70,190 (Interferon) and for c87,555 (Copolymer). In Slovakia a relapse-
free patient values c60,357 (Natalizumab) versus c58,043 (Interferon) and c19,921 
(Copolymer). a relapse-free patient in Slovenia values c59,108 (Natalizumab) versus 
c66,202 (Interferon) and c84,207 (Copolymer). In Austria a relapse-free patient values 
c58,423 (Natalizumab) versus c71,906 (Interferon) and c89,591 (Copolymer). CON-
CLUSIONS: In Czech Republic, Slovenia, and Austria, treatment of MS with Natali-
zumab is more cost-effective than Interferon resp. Copolymer 1 therapy. Switching to 
effective and more expensive alternatives does not account for higher health care costs.
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OBJECTIVES: To calculate and compare the incremental cost-utility ratios for stan-
dard antiepileptic drug (AED) therapy with and without adjunctive lacosamide in 
patients with uncontrolled partial-onset seizures. METHODS: The model simulated 
the treatment pathway of a hypothetical cohort of 1000 patients over 2 years from 
the perspectives of the National Health Service (NHS) in Scotland and the Spanish 
Healthcare System (SNS) in 2008. a decision tree was split into four phases of six 
months each during which patients can become seizure free, experience a seizure 
reduction (responder deﬁ ned as ≥50% reduction in seizures), or withdraw due to 
non-response. The standard therapy arm included carbamazepine, lamotrigine, leve-
tiracetam, topiramate, and valproate. The likelihood of being in a particular health 
state has been estimated from clinical data. The cost of general practitioner visits, 
outpatient visits, hospitalizations and emergency department visits were included. 
Costs and utility values attached to various health states were taken from the published 
literature. RESULTS: Lacosamide adjunctive therapy was associated with 6730 
avoided seizures and a gain of 38 quality adjusted life-years (QALYs), compared to 
the standard therapy arm within the two-year timeframe. Treatment with lacosamide 
was associated with a cost of £113 and c107 per seizure avoided, and £20,017 and 
c22,771 per QALY gained versus standard therapy in Scotland and Spain, respectively. 
Results calculated for 6-, 12- and 18-month follow-up showed respective incremental 
cost-utility ratios of £23,479, £21,422 and £20,998 in Scotland, and c23,771, c20,703 
and c21,778 in Spain. Using a willingness-to-pay threshold of £30,000 per QALY, 
80% of the simulations in Scotland and 74.2% in Spain fell below this value after 2 
years of treatment. CONCLUSIONS: Lacosamide was shown to be a cost-effective 
adjunctive treatment in patients with uncontrolled partial-onset epilepsy in Scotland 
and Spain.
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DUODENAL LEVODOPA INFUSION VERSUS STANDARD TREATMENT 
IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE IN SWEDEN
Willis M1, Gradl B2
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BACKGROUND: Advanced Parkinson’s disease (APD) severely impacts the quality 
of life (QoL) for both patients and their caregiver and is associated with high health 
care and societal costs. The treatment options for those patients are limited. Duodenal 
levodopa infusion (DLI), an orphan drug, has shown to restore symptom control and 
to improve QoL substantially for both patients and their carers. OBJECTIVES: To 
evaluate the cost-utility of DLI versus standard treatment (including oral treatment 
and subcutaneous dopamine agonists) in patients with advanced PD in Sweden. 
METHODS: A stochastic Markov-based simulation model was developed. Health was 
described by 12 health states reﬂ ecting 4 categories of “OFF” time and 3 severity 
stages as measured by the Hoehn & Yahr scale. The clinical effect for both treatment 
arms was derived from published clinical trials; costs and QoL utilities were taken 
from an interim analysis of the ongoing DAPHNE study. The base case simulated 5 
years with costs/effects discounted by 3%. The societal perspective was adopted. 
RESULTS: The model estimated an improvement from 0.68 to 1.30 QALYs and a 
cost increase from 1,410,643 (c147,108) to SEK 1,674,295 (c174,603) for DLI versus 
standard treatment, leading to an incremental cost-effectiveness ratio (ICER) of 
around SEK 420,000 (c43,800) per QALY gained. The ICER for nearly 90% of the 
cohorts fell below SEK 655,000 (c68,306), the willingness-to-pay threshold often cited 
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for Sweden [1]. Sensitivity analysis was associated with ICERs ranging up to SEK 
900,000 (c93,856) per QALY gained. CONCLUSIONS: Due to the data limitations, 
HE modeling in the orphan drug setting is challenging. Analysis could be performed 
as requested by Sweden’s Dental and Pharmaceutical Beneﬁ ts Agency (TLV), however, 
providing evidence that health beneﬁ ts can provide good value for money even for an 
orphan population. DLI received a positive reimbursement recommendation by the 
TLV. [1] Persson U, Hjelmgren J (2003).
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EARLY-STAGE PARKINSON’S DISEASE IN SCOTLAND
Benhaddi H, Gunn A
UCB Pharma S.A., Brussels, Belgium
OBJECTIVES: To evaluate the cost-effectiveness of rotigotine transdermal patch as 
monotherapy in early-stage Parkinson’s disease (PD) compared to ropinirole and other 
dopamine agonists (DA) from the NHS perspective in Scotland. METHODS: a deci-
sion-analytic model was developed, based on treatment of an early-stage PD patient 
(Hoehn and Yahr-stage 2); treatment arms were rotigotine, ropinirole, and a DA 
practice comparator including ropinirole, cabergoline and pramipexole. 5-year and 
10-year time horizons were considered for patients who remained on monotherapy 
only. The economic evaluation is a cost-utility analysis with health outcomes expressed 
in Quality Adjusted Life-years (QALY) gained in 2006. Costs relating to drug acquisi-
tion, PD severity, falls, occurrence of motor complications and other complications/
adverse events/co-morbidities were considered in the model. Efﬁ cacy and safety data 
were estimated with a meta-analysis. Quality of life was measured using EQ-5D. Data 
on medical resource use was obtained via expert interviews and literature review. 
Costs and effects were discounted at the rate of 3.5%. RESULTS: After 5 years, treat-
ment with rotigotine transdermal patch resulted in an estimated 2.30 QALYs, slightly 
higher than with ropinirole (2.26) and the DA practice comparator (2.27). 10-year 
outcomes were 3.22, 3.17 and 3.17 QALYs for rotigotine, ropinirole and DA practice 
comparator, respectively. Total costs for rotigotine, ropinirole and DA practice com-
parator were £34,748, £37,694 and £36,459 respectively after 5 years and £79,477, 
£84,120 and £81,631, respectively after 10 years. With a willingness-to-pay of 
£20,000 per QALY gained, there is a 90% probability that rotigotine is cost-effective 
relative to ropinirole, and a 85% probability of cost-effectiveness relative to the DA 
practice comparator for both 5-year and 10-year time horizons. CONCLUSIONS: 
Based on the model, rotigotine may be considered a dominant strategy over ropinirole 
and DA practice comparator in the treatment of early-stage PD at 5-year and 10-year 
time horizons.
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SUMATRIPTAN IN SWEDEN
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OBJECTIVES: In 2005 the Swedish pharmaceutical beneﬁ ts board published a review 
concluding that rizatriptan 10  mg was one of the most cost-effective triptans for 
treating migraine, although efﬁ cacy differences among the triptan class were generally 
small. However, since the review, the price of sumatriptan has declined due to generic 
product entry. In this study, we sought to investigate the cost-effectiveness of rizat-
riptan versus generic sumatriptan. METHODS: A published Canadian decision-ana-
lytic model (Thompson et al., Pharmacoeconomics 2005) was adapted to estimate 
treatment costs and effects of rizatriptan 10 mg versus (generic) sumatriptan in a single 
migraine attack over a 24-hour time-frame in Sweden. Values modiﬁ ed from the 
published model were the substitution of Swedish health care and productivity costs, 
and updated data on 2-hour and 2–24 hour pain freedom (including results from more 
recent head-to-head trials of the comparators). As both sumatriptan 50 mg and 
100 mg are marketed in Sweden, and have comparable efﬁ cacy proﬁ les, averaged data 
for the two doses were used as a comparator to rizatriptan 10 mg. RESULTS: From 
a societal perspective, including both health care and productivity costs, the compari-
son of rizatriptan 10 mg versus (generic) sumatriptan resulted in cost-savings of ~ 5 
SEK, and greater QALYs for rizatriptan 10 mg. Inclusion of health care costs only, 
yielded a cost-effectiveness ratio for rizatriptan vs. sumatriptan of 343,929 SEK/
QALY. CONCLUSIONS: Given the data and assumptions used, in a single attack 
model, rizatriptan 10 mg was found to have a cost-effectiveness ratio compared to 
(generic) sumatriptan within the range typically regarded as cost-effective in Sweden. 
These ﬁ ndings suggest that there is reason to explore the cost-effectiveness of phar-
maceutical and other medical interventions with large differences in acquisition cost 
even though efﬁ cacy differences may appear to be small.
PND30
COST-UTILITY ANALYSIS OF LACOSAMIDE ADJUNCTIVE THERAPY IN 
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OBJECTIVES: This study aims at evaluating the incremental cost-effectiveness ratio 
(ICER) for lacosamide compared with standard therapy alone from the perspective of 
the Belgian health care payer in 2010. METHODS: A decision tree simulating the 
treatment pathway of a hypothetical cohort of 1,000 patients over two years was split 
into four phases of six months each during which patients can become seizure free, 
experience a seizure reduction (deﬁ ned as ≥50% reduction in seizures), or withdraw 
due to non-response. The antiepileptic drugs (AEDs) included in the standard therapy 
arm were extracted from the pivotal trials and included carbamazepine, lamotrigine, 
levetiracetam, topiramate and valproate. Health state probabilities, seizure frequency 
and utility values were taken from lacosamide trials or from the literature. Costs of 
general practitioner visits, outpatient visits, hospitalizations and emergency depart-
ment visits were included. Resource use was estimated by a Belgian panel of eight 
neurologists. Costs were discounted at a rate of 3% and consequences at a rate of 
1.5%. RESULTS: Over a 24-month period, standard AED therapy plus lacosamide 
led to a reduction of 7 seizures, an increase of 0.038 quality-adjusted life-years, and 
a cost decrease of c3619 per patient as compared with standard therapy alone. Results 
were also calculated for a 6-, 12- and 18-month follow-up. Lacosamide plus AED 
therapy dominated versus standard therapy alone. Using a willingness to pay of 
c30,000 per quality-adjusted life-year, the net monetary beneﬁ t of standard antiepi-
leptic drug therapy plus lacosamide amounted to c4,754. The probability of standard 
AED therapy plus lacosamide being cost-effective was 97.3% at 6 months, 99.8% at 
12 months, 99.9% at 18 months, and 100% at 24 months. CONCLUSIONS: In 
epileptic patients who are difﬁ cult to treat with other AEDs, standard AED therapy 
plus lacosamide appears to be a cost-effective alternative. 
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IMPACT OF AN ADHERENCE PROGRAM, RUN AS A TELEPHONE 
INTERVENTION ON COMPLIANCE WITH SUBCUTANEOUS 
INTERFERON Â-1A FOR MULTIPLE SCLEROSIS PATIENTS USING A 
MAIL-ORDER PHARMACY
Papademetriou E1, Levin R1, Tuennermann M2, Lammers V2, Aubert RE1
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OBJECTIVES: Quasi-experimental analysis to determine the effect of an opt-in tele-
phone intervention on adherence in patients using subcutaneous interferon β-1a, 
which is indicated for relapsing-remitting multiple sclerosis. Drop-out reasons, side-
effects, and expectations of therapy are described. METHODS: Customers of a mail-
order pharmacy that services Germany who ordered subcutaneous interferon β-1a 
were targeted for enrollment in a free program that included an initial counseling call, 
optional e-mail reminders for the next doctor’s consultation and prescription, and 
ongoing counseling calls. Patients enrolled in the program for at least 6-months were 
included in the analysis and compared to patients that did not enter the program over 
the same time period. Proportion of days covered (PDC) was calculated for each group 
and compared using analysis of variance. Enrollees in the program were administered 
a questionnaire at the initial welcome call addressing their expectations of therapy, 
and again during each counseling call regarding their compliance behavior, and side 
effects. RESULTS: Patients in the adherence program showed an unadjusted PDC 
8.2% higher than the control, F(1.247) = 13.44, p = 0.0003. One program patient 
switched drugs compared to six control group patients. a total of 21% of enrolled 
subjects reported missing at least one dose. Side-effects included pain/inﬂ ammation at 
the site of injection (24.41%), fatigue (20.73%), headaches (17.06%), and ﬂ u-like 
symptoms (9.71%). Exacerbations were reported by 15.7% of patients. Patients’ had 
expectations that therapy would prolong the distance between exacerbations (23.36%) 
and slow the progression of disability due to the disease (21.28%). CONCLUSIONS: 
Actively recruiting patients into an optional adherence program signiﬁ cantly increased 
the compliance rate for relapsing-remitting multiple sclerosis patients using subcutane-
ous interferon β-1a. Side effects experienced by enrolled patients were consistent with 
the package insert. Limitations include a potential bias between patients that agree to 
the program vs. those that do not, as well as the lack of additional questionnaire data 
from the control group.
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INFLUENCE OF AGE ON REFILL-ADHERENCE RATES OF ANTI-
EPILEPTIC DRUGS IN SOUTH AFRICA
Van Zyl T, Lubbe MS, Serfontein JHP, Rakumakoe DM
North-West University, Potchefstroom, South Africa
OBJECTIVES: To investigate the possible inﬂ uence of age on the reﬁ ll-based adher-
ence rates of anti-epileptic drugs. METHODS: A retrospective drug utilization review 
was performed on medicine claims data of a pharmacy beneﬁ t management company 
in South Africa. Reﬁ ll-based adherence rates were calculated for 64,457 anti-epileptic 
drugs that were prescribed more than once during a four-year period (January 1, 2005 
to December 2008). The reﬁ ll-based adherence rate was calculated per trade name by 
using the following equation: Reﬁ ll-Adherence rate = (total number of days of anti-
epileptic drugs supplied—days supplied at the last reﬁ ll)/(date last claimed—date ﬁ rst 
claimed). [RSA Rand (R)/$US = 6.38112 (2005); 6.78812 (2006); 7.06926 (2007) and 
8.27505 (2008)]. RESULTS: Only 30.5% (n = 19 635) of anti-epileptic drugs had 
reﬁ ll-adherence rates between between 90% and 110%. The majority of anti-epileptic 
drugs (58.9%; n = 37 962) had reﬁ ll-adherence rates below 90% that accounted for 
39.2% (n = R 57 599 838) of the total cost of all anti-epileptic drugs (N = R146 863 
755) included in these calculations. Anti-epileptic drugs with reﬁ ll-adherence rates 
>110% (10,7%; n = 6 860) accounted for 6.7% (R9 782 864) of the total cost of all 
anti-epileptic drugs. The average reﬁ ll-adherence rate decreased with nearly 10% from 
